Combined CTLA-4 and PD-1 inhibition a single institute in-depth analysis of toxicity and efficacy in patients treated at the Dana-Farber Cancer Institute
PURPOSE: The purpose of this study was to compare the rate of grade 3-4 immune related adverse events (irAEs) in patients with advanced metastatic melanoma treated with the combined anti-CTLA-4 and anti-PD-immune-therapy at the Dana Farber Cancer Institute(DFCI), to that of the published rate of gra...
| Main Author: | |
|---|---|
| Language: | en_US |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/26950 |